Key facts
- Paul L. Berns has 5 issuer positions tracked on this page.
- Estimated disclosed ownership value: $27,211,767.
- Recent insider filing activity is available below.
Insider Trading & Ownership of Paul L. Berns
- Location
- Watertown, MA
- Summary
- The estimated net worth of Paul L. Berns is at least $27,211,767 dollars as of 19 Feb 2026. Paul L. Berns is the Title: Chief Executive Officer and Chairman of the Board, Director of Neumora Therapeutics, Inc. and owns shares of Neumora Therapeutics, Inc. (NMRA) stock worth about $26.22M. Paul L. Berns is the Director of Jazz Pharmaceuticals plc and owns shares of Jazz Pharmaceuticals plc (JAZZ) stock worth about $987.6K.
- Signature
- /s/ Michael Milligan, as Attorney-in-Fact for Paul L. Berns
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Paul L. Berns and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
Change
- Largest disclosed position: Neumora Therapeutics, Inc. ($26,224,179).
- Past-year value change for that position: -$34,459.
Research use
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Paul L. Berns
NMRA
Forms 3/4/5
Neumora Therapeutics, Inc.
- Holdings value
- $26,224,179
- Past year net change
- -$34,459
- Change %
- -0.13%
- Report period
- 17 Feb 2026
JAZZ
Forms 3/4/5
Jazz Pharmaceuticals plc
- Relationship
- Director
- Holdings value
- $987,588
- Past year net change
- Change %
- Report period
- 05 Aug 2021
MTSR
Forms 3/4/5
Metsera, Inc.
- Relationship
- Director
- Holdings value
- $0
- Past year net change
- Change %
- Report period
- 13 Nov 2025
EQRX
Forms 3/4/5
EQRx, Inc.
- Relationship
- Director
- Holdings value
- Past year net change
- Change %
- Report period
- 09 Nov 2023
UBX
Forms 3/4/5
Unity Biotechnology, Inc.
- Relationship
- Director
- Holdings value
- Past year net change
- Change %
- Report period
- 21 Jun 2024
Insider Transactions Reported by Paul L. Berns:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.